Table 1. Patient Characteristics Compared by Conditioning Cohorts.
| Myeloablative |
Nonmyeloablative |
||
|---|---|---|---|
| N = 65 |
N = 76 |
||
| N (%) | N (%) | P-value | |
| Age, years-median (range) | 42 (4-58) | 48 (19-66) | <.01 |
| Gender, male | 40 (62) | 46 (61) | NS |
| Disease | |||
| NHL* | 62 (95) | 53 (70) | <.01 |
| HL | 3 (5) | 23 (30) | |
| Disease status at transplant | |||
| CR1+ | 18 (28) | 11 (14) | NS |
| PR1+ | 37 (57) | 49 (64) | |
| Minimally responsive disease | 10 (15) | 16 (21) | |
| Prior autologous transplant | |||
| Yes | 0 | 30 (39) | <.01 |
| No | 65 (100) | 46 (61) | |
| Donor | |||
| Matched related | 49 (75) | 32 (42) | <.01 |
| Unrelated/mismatched related | 10 (15) | 11 (14) | |
| Umbilical cord blood | 6 (9) | 33 (43) | |
| Stem cell source | |||
| Bone marrow | 5 (8) | 8 (10) | <.01 |
| PBSC | 54 (83) | 35 (46) | |
| Umbilical cord blood | 6 (9) | 33 (43) | |
| Donor/recipient CMV serostatus | |||
| Both negative | 21 (32) | 40 (53) | .02 |
| Either positive | 44 (68) | 36 (47) | |
| Conditioning regimen† | |||
| Cy120/TBI (1320 cGy) | 49 (75) | ||
| Bu16/Cy120 | 12 (18) | ||
| Flu75/Cy120/TBI (1320 cGy) | 4 (6) | ||
| Flu200/Cy50/TBI (200 cGy) | 48 (64) | ||
| Flu200/Bu8/TBI (200 cGy) | 21 (27) | ||
| Bu8/Clad50/TBI (200 cGy) | 7 (9) | ||
| GVHD prophylaxis | |||
| CSA/Methotrexate | 59 (91) | 0 | <.01 |
| CSA/MMF | 6 (9) | 76 (100) | |
| Year of transplant | |||
| 1997-2000 | 31 (48) | 10 (13) | <.01 |
| 2001-2004 | 34 (52) | 66 (87) | |
| Time from diagnosis to transplant (month) | 16 (3-106) | 30 (8-247) | <.01 |
GVHD indicates graft-versus-host disease; PBSC, peripheral blood stem cells; NHL, non-Hodgkin’s lymphoma; CR, complete remission; PR, partial remission; CMV, cytomegalovirus; HL, Hodkin’s lymphoma; TBI, total-body irradiation.
Mantle cell lymphoma (MA, n = 13; NMA, n = 7); indolent lymphomas including follicular and small lymphocytic lymphoma (MA, n = 11; NMA, n = 24); diffuse large cell lymphoma (MA, n = 7; NMA, n = 11); T cell lymphomas (MA, n = 8; NMA, n = 6); and other lymphomas including aggressive lymphomas such as transformed or Burkitt’s lymphomas (MA, n = 23; NMA, n = 5).
Cy120 = cyclophosphamide 120 mg/kg total dose; Cy50 = Cyclophosphamide 50 mg/kg total dose; Bu16 = Busulfan 16 mg/kg total dose; Bu8 = Busulfan 8 mg/kg total dose; Flu75 = Fludarabine 75 mg/m2total dose; Flu200 = Fludarabine 200 mg/m2total dose; Clad50 = Cladrabine 50 mg/m2 total dose.